Wei J, Luo C, Wang Y, Guo Y, Dai H, Tong C, et al. PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. J Immunother Cancer. 2019;7:209 pubmed publisher

Meggyes M, Feik T, Nagy D, Polgar B, Szereday L. CD8 and CD4 Positive NKT Subpopulations and Immune-Checkpoint Pathways in Early-Onset Preeclampsia and Healthy Pregnancy. Int J Mol Sci. 2023;24: pubmed publisher

Lao L, Zeng W, Huang P, Chen H, Jia Z, Wang P, et al. CD8+ T cell-Dependent Remodeling of the Tumor Microenvironment Overcomes Chemoresistance. Cancer Immunol Res. 2023;11:320-338 pubmed publisher

Edwards C, Sette A, Cox C, Di Fiore B, Wyre C, Sydoruk D, et al. The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. Br J Cancer. 2021;: pubmed publisher

Geuijen C, Tacken P, Wang L, Klooster R, Van Loo P, Zhou J, et al. A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. Nat Commun. 2021;12:4445 pubmed publisher

Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H, et al. The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity. Mol Ther. 2021;29:1794-1807 pubmed publisher

Katsuyama E, Suárez Fueyo A, Bradley S, Mizui M, Marin A, Mulki L, et al. The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections. Cell Rep. 2020;30:112-123.e4 pubmed publisher

Cunningham R, Holland M, McWilliams E, Hodi F, Severgnini M. Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry. J Biol Methods. 2019;6:e114 pubmed publisher